

Fabien B Vincent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1062459/publications.pdf>

Version: 2024-02-01

39
papers

1,800
citations

586496

16
h-index

445137

33
g-index

46
all docs

46
docs citations

46
times ranked

3241
citing authors

#	ARTICLE	IF	CITATIONS
1	Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis. <i>Lupus Science and Medicine</i> , 2022, 9, e000625.	1.1	24
2	GILZ Regulates the Expression of Pro-Inflammatory Cytokines and Protects Against End-Organ Damage in a Model of Lupus. <i>Frontiers in Immunology</i> , 2021, 12, 652800.	2.2	7
3	Granulocyte colony-stimulating factor is not pathogenic in lupus nephritis. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 758-770.	1.3	6
4	Long-term exposure to monoclonal anti-TNF is associated with an increased risk of lymphoma in BAFF-transgenic mice. <i>Clinical and Experimental Immunology</i> , 2021, 205, 169-181.	1.1	0
5	Circulating Interleukin-37 Levels in Healthy Adult Humans – Establishing a Reference Range. <i>Frontiers in Immunology</i> , 2021, 12, 708425.	2.2	7
6	Associations of metabolic syndrome in SLE. <i>Lupus Science and Medicine</i> , 2020, 7, e000436.	1.1	14
7	Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2020, 7, e000375.	1.1	15
8	Measuring MIF in Biological Fluids. <i>Methods in Molecular Biology</i> , 2020, 2080, 47-56.	0.4	1
9	Serum and urinary macrophage migration inhibitory factor (MIF) in primary Sjögren's syndrome. <i>Joint Bone Spine</i> , 2019, 86, 393-395.	0.8	4
10	Effect of storage duration on cytokine stability in human serum and plasma. <i>Cytokine</i> , 2019, 113, 453-457.	1.4	23
11	Novel Methods of Incorporating Time in Longitudinal Multivariate Analysis Reveals Hidden Associations With Disease Activity in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2019, 10, 1649.	2.2	4
12	Analysis of serum interleukin-1 α , IL-1 β and IL-18 in patients with systemic sclerosis. <i>Clinical and Translational Immunology</i> , 2019, 8, e1045.	1.7	16
13	Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus. <i>Clinical and Translational Immunology</i> , 2019, 8, e01047.	1.7	25
14	Serum soluble Fas and Fas ligand (FasL) in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 254-256.	0.4	1
15	Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2018, 5, e000277.	1.1	10
16	Analysis of serum macrophage migration inhibitory factor and Dopachrome tautomerase in systemic sclerosis. <i>Clinical and Translational Immunology</i> , 2018, 7, e1042.	1.7	14
17	Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 2029-2040.	0.8	16
18	Analysis of Serum Interleukin (IL)-1 β and IL-18 in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2018, 9, 1250.	2.2	89

#	ARTICLE	IF	CITATIONS
19	Effet des concentrations s�riques r�siduelles d'anti-TNF et d'anticorps anti-m�dicaments (ADAb) sur l'efficacit� th�rapeutique � court terme apr�s switch vers un autre anti-TNF dans la polyarthrite rhumato�de et la spondyloarthrite axiale. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 352-355.	0.0	0
20	Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis. <i>Joint Bone Spine</i> , 2016, 83, 595-597.	0.8	4
21	Seasonal influenza vaccine coverage of patients on biotherapy for inflammatory joint disease in Normandy, France. <i>Joint Bone Spine</i> , 2016, 83, 465-467.	0.8	0
22	Maintien des traitements anti-TNF dans le rhumatisme psoriasique: �tude r�trospective monocentrique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016, 83, 32-36.	0.0	0
23	Influenza vaccination status in rheumatoid arthritis and spondyloarthritis patients receiving biologic DMARDs. <i>Joint Bone Spine</i> , 2016, 83, 237-238.	0.8	9
24	The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells. <i>Leukemia</i> , 2016, 30, 163-172.	3.3	69
25	BAFF-driven autoimmunity requires CD19 expression. <i>Journal of Autoimmunity</i> , 2015, 62, 1-10.	3.0	28
26	Tumor necrosis factor inhibitors continuation rates in patients with psoriatic arthritis: A French retrospective monocentre study. <i>Joint Bone Spine</i> , 2015, 82, 377-378.	0.8	0
27	The BAFF/APRIL system in SLE pathogenesis. <i>Nature Reviews Rheumatology</i> , 2014, 10, 365-373.	3.5	338
28	S-15. <i>Cytokine</i> , 2014, 70, 24.	1.4	0
29	What has the Young Physician Leaders Programme achieved?. <i>Lancet, The</i> , 2014, 384, 26-27.	6.3	2
30	Roles of ligands from the TNF superfamily in B cell development, function, and regulation. <i>Seminars in Immunology</i> , 2014, 26, 191-202.	2.7	25
31	Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia. <i>Leukemia</i> , 2014, 28, 2005-2015.	3.3	43
32	The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 203-215.	3.2	319
33	The TACI Receptor Regulates T-Cell-Independent Marginal Zone B Cell Responses through Innate Activation-Induced Cell Death. <i>Immunity</i> , 2013, 39, 573-583.	6.6	58
34	Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 165-178.	0.5	315
35	Mesangial immunoglobulin (Ig)A glomerulonephritis in a patient with rheumatoid arthritis treated with abatacept. <i>Joint Bone Spine</i> , 2013, 80, 660-663.	0.8	15
36	Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. <i>Lupus</i> , 2013, 22, 873-884.	0.8	74

#	ARTICLE	IF	CITATIONS
37	Focus on systemic lupus erythematosus in Indigenous <sc>A</sc>ustralians: towards a better understanding of autoimmune diseases. Internal Medicine Journal, 2013, 43, 227-234.	0.5	23
38	Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Research and Therapy, 2013, 15, R97.	1.6	122
39	BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. Immunology and Cell Biology, 2012, 90, 293-303.	1.0	79